Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Farzan: Preventing HIV-1 transmission with a novel entry inhibitor, eCD4-Ig |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Screening |
| Species: | Non-Organism Study |
| Stage: | Assays Completed |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
eCD4 neutralization
Description
CAVD 812 is an immunogenicity study evaluating eCD4-Ig variants.
Sign in to see full information about this study and to download study data.
Products
No Products used in studyIntegrated data
No integrated data is available for this study.
Non-integrated data
NAb Ig